What it's actually good for
TUDCA is a bile acid your liver already makes in small amounts — conjugating taurine onto ursodeoxycholic acid (UDCA), the same compound sold as the prescription drug Ursodiol. That existing pharmaceutical history is why TUDCA has a real evidence base at all: it has been tested in cirrhosis, cholestasis, and liver-transplant patients for decades, and more recently in obesity-related insulin resistance and inflammatory bowel disease. The mechanism — acting as a "chemical chaperone" that eases endoplasmic reticulum (ER) stress and improves protein folding in stressed cells — is legitimate and well studied in animal models.
Where the story gets stretched is the jump from "clinically useful bile acid for diagnosed liver and metabolic conditions" to "daily liver detox everyone should take." That second claim is the one driving current TUDCA sales, including from wellness-medicine figures who list it in liver-support stacks. It has essentially no direct human evidence behind it — every clinical trial below enrolled people with a diagnosed condition, not healthy people looking to "support" a liver that isn't in trouble.
What the research says
Cirrhosis and cholestatic liver disease (Grade B). A 2013 double-blind RCT randomized cirrhosis patients to TUDCA or UDCA (750 mg/day, 6 months) and found TUDCA significantly reduced ALT, AST, and ALP — markers of liver inflammation — and outperformed UDCA on those biochemical measures. But the trial had only 18 evaluable patients, ran just 6 months, and neither drug changed fibrosis markers. This is real signal in a diagnosed population, not proof of long-term benefit.
Insulin sensitivity (Grade B). A placebo-controlled RCT gave 20 obese, insulin-resistant adults 1,750 mg/day of TUDCA for 4 weeks and found roughly 30% improvements in hepatic and muscle insulin sensitivity. Notably, it did not reduce measured liver fat and had no effect in adipose tissue — a reminder that "improves insulin sensitivity" and "fixes fatty liver" are not the same claim, even though TUDCA marketing often conflates them.
Ulcerative colitis (Grade C). A 2025 trial found 6 weeks of TUDCA lowered disease activity scores and mucosal ER stress in patients with active UC. It's a genuinely interesting mechanistic result, but it was open-label with no placebo arm and only 13 completers — exactly the kind of early signal that needs a controlled trial before it means anything for treatment decisions.
Healthy-person "liver detox" (unsupported). A Cochrane review of bile acids (including TUDCA) in liver-transplant patients — the population with the most trial data — found no significant benefit on mortality, rejection, or retransplantation, despite bile acids being safe and well tolerated. If bile acid supplementation doesn't clearly move outcomes in patients with damaged livers under close monitoring, there's no clinical basis for taking it as a preventive "detox" when your liver isn't compromised in the first place.
How much, and which form
Clinical trials used 750-2,000 mg/day, split into two or three doses with food, for defined conditions over weeks to months. There's no established consumer dose for general wellness use — dosing above was set for cirrhosis, insulin resistance, or active colitis under study monitoring, not for someone without a diagnosed condition.
Safety & interactions
TUDCA is generally well tolerated across trials, with gastrointestinal upset (diarrhea, bloating, nausea) as the main issue, more common near or above 1,500 mg/day. Because it's a bile acid, anyone with gallstones, biliary obstruction, or existing liver disease should only use it under a clinician's supervision. It hasn't been studied in pregnancy or lactation. This is informational, not medical advice — check with a clinician before starting, especially if you have any liver or biliary condition.
How we picked the brand
A TUDCA product earns a spot when it's pure TUDCA with no proprietary blends, doses in the range actually used in trials (allowing you to match a clinical protocol if a clinician recommends one), is made in a cGMP facility, and publishes third-party testing.